<DOC>
	<DOC>NCT02571374</DOC>
	<brief_summary>This is a double blind randomized trial in which patients with colorectal cancer undergoing surgery will be selected to receive either a symbiotic formulation or placebo. The researchers will compare incidence of surgical site infection between the study groups.</brief_summary>
	<brief_title>Symbiotics to Prevent Postoperative Infection in Colorectal Cancer</brief_title>
	<detailed_description>This is a double blind randomized trial in which patients with colorectal cancer undergoing surgery will be randomly selected to receive either a symbiotic formulation or placebo during the perioperative period. The researchers will compare incidence of surgical site infection, detected by clinical examination and complementary tests (CT scans, X-rays, microbiological and hematological tests) between the study groups.</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Surgical Wound Infection</mesh_term>
	<criteria>Adults between 18 and 85 years old; Colorectal cancer patients. Ability to understand and signing the informed consent Pregnancy (early diagnosis) Reduced intellectual level that could prevent proper understanding of the objectives of the study Patients with rectal cancer undergoing neoadjuvant treatment (chemotherapy and radiotherapy) Use of products with prebiotic, probiotic and / or symbiotic function or fiber module; by more than 3x a week Refusal to participate and / or to sign the Consent Form Free and Clear</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>symbiotic</keyword>
	<keyword>colorectal cancer</keyword>
</DOC>